Healthcare in Europe is at a crossroads. It faces increasing challenges on a number of fronts; at the same time, technological and scientific advances offer new opportunities to solve these challenges. Bridging the gap to address today’s health and translational challenges will require a multi-sector Public-Private Partnership.
Five industry associations representing pharmaceutical, biotech and medical technologies industries operating in Europe (COCIR, EFPIA, MedTech Europe, EuropaBio and Vaccines Europe) have come together to work on a Strategic Agenda for Innovation in Healthcare. This Agenda falls in the framework of the proposed European Health Innovation Public-Private Partnership under Horizon Europe. Its objective is to guide future public-private research & innovation that would contribute – alongside other European research funding instruments – to addressing some key European healthcare challenges in an integrated manner.
Today, the private sector is interested to invest in a new health Public-Private Partnership and would like invite citizens, patients, health and research communities, national authorities, academia and scientific societies to provide their input to make sure that this Strategic Agenda aligns with the needs of European health and research communities.
You have an opportunity to learn more about the proposed partnership and ask questions during a dedicated webinar on 4 November 14.00 CET – register here!
You can contribute to this consultation by filling in the online questionnaire until 24 November midnight.
EIBIR welcomes the implementation of the Public-Private Partnership within the next European Commission’s research framework programme Horizon Europe, as it will warrant the integration between industry and academia, provide funding opportunities that are necessary to address current challenges in health care research and help to maintain Europe at the forefront of medical innovation. It provides a unique opportunity to position biomedical imaging more prominently for years to come.